Abstract
Chemoresistance blocks the efficient treatment of epithelial ovarian cancer, which is the most lethal of all gynecological cancers. Cancer stem cells are believed to be at least partially responsible for the development of chemoresistance. In this study, the effect of cisplatin (CDP) on the enrichment and proliferation of cancer stem-like cells (CSLCs) was investigated, and the underlying mechanisms of action were elucidated. An in vitro anchor-free system was employed to enrich CSLCs from the SKOV3 human epithelial ovarian cancer cell line. Our results showed that treatment with low concentrations of CDP resulted in better-enriched CSLCs, with higher proliferative activities. Low dose of CDP was found to induce the expression of chemokine (C-X-C motif) receptor 4 (CXCR4), which is an important stemness marker in cancer stem cells as well as a promising therapeutic target for ovarian cancer treatment. Results also showed that overexpressed CXCR4 generated chemoresistance. Based on these results, it may be concluded that, at low concentrations, CDP itself contributes to the development of drug resistance. This finding provides novel insight into the mechanisms underlying chemoresistance and has significant therapeutic implicatio...Continue Reading
References
May 21, 2003·Genes & Development·Gabriela DontuMax S Wicha
Jan 9, 2004·Proceedings of the National Academy of Sciences of the United States of America·Toru KondoTetsuya Taga
Apr 2, 2005·Nature Reviews. Cancer·Michael DeanSusan Bates
Apr 19, 2005·Cancer Research·Sharmila A BapatNawneet K Kurrey
Jul 19, 2005·Cancer Research·Lubna PatrawalaDean G Tang
Sep 28, 2006·Annual Review of Medicine·Piero DalerbaMichael F Clarke
Sep 26, 2007·International Journal of Cancer. Journal International Du Cancer·Hiroaki KajiyamaFumitaka Kikkawa
Jun 4, 2008·Cancer Research·Shu ZhangKenneth P Nephew
Oct 10, 2008·Annual Review of Pathology·Kathleen R Cho, Ie-Ming Shih
Mar 17, 2009·Cancer Letters·Alexander KrohnEckhard Alt
Aug 14, 2010·Acta Biochimica Et Biophysica Sinica·Li MaLihe Guo
Feb 8, 2011·CA: a Cancer Journal for Clinicians·Ahmedin JemalDavid Forman
May 28, 2011·Journal of Cellular Biochemistry·Ardian LatifiNuzhat Ahmed
Sep 6, 2011·Oncogene·L GalluzziG Kroemer
Sep 22, 2011·Science Signaling·Hiroshi YagiJ Silvio Gutkind
Jan 13, 2012·Nature Reviews. Cancer·Long V NguyenConnie J Eaves
Aug 3, 2012·Nature·Gregory DriessensCédric Blanpain
Aug 3, 2012·Nature·Jian ChenLuis F Parada
Aug 24, 2012·International Journal of Clinical Oncology·Tamotsu Sudo
Nov 10, 2012·Cancer Letters·Rosemary FosterBo R Rueda
Mar 30, 2013·Molecular Cancer·Khalid AbubakerNuzhat Ahmed
Jul 3, 2013·Molecular Aspects of Medicine·Nuzhat AhmedJock K Findlay
Jul 23, 2013·Cell Proliferation·X LuoD Lai
Jan 9, 2014·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Jan 11, 2014·PloS One·Jianqun LiaoKunle Odunsi
May 31, 2014·Cell Death & Disease·L GalluzziG Kroemer
Sep 10, 2014·Cancers·Genevieve HousmanSibaji Sarkar
Oct 17, 2014·International Journal of Molecular Medicine·Yi-Fei ChenDongmei Lai
Citations
May 27, 2014·PloS One·Yin XiongElectron Kebebew
Feb 15, 2017·PloS One·Hyun Hee LeeBenedict Law
Mar 22, 2018·Oncotarget·Pengming SunJalid Sehouli
Nov 21, 2019·International Journal of Oncology·Annie Riera LealAna Laura Pereira-Suárez
Jul 10, 2020·Cancer Research·Stine E Weis-BankePaul A C Cloos
Apr 9, 2021·BioMed Research International·Jing ZhangJin Chen
Jul 29, 2021·British Journal of Cancer·Zhigeng ZouXiying Yu